PRESS RELEASE

from MAUNA KEA TECHNOLOGIES (EPA:MKEA)

Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital

 

Monthly information regarding the total number of voting rights and shares comprising the share capital

Article L233-8-II of the Commercial Code

Article 223-16 of the General Regulations of the AMF

 

 

Paris, May 17th, 2024,

Listing: Euronext Growth Paris

ISIN code: FR0010609263, Ticker: ALMKT

Website: www.maunakeatech.com 

 

 

Date

Number of shares comprising the capital in circulation

Total number of voting rights

 (1)

Gross Total    

 (2)

Net Total     

April 30th, 2024

61,598,117 

62,637,301

62,574,815

(1)                     image
The gross number of voting rights (or "theoretical" voting rights) serves as the basis for calculating the thresholds. In accordance with Article 223-11 of the General Regulations of the AMF, this number is calculated on the basis of all shares carrying voting rights, including shares without voting rights. 

(2)                     The net number of voting rights (or voting rights "exercisable in General Meeting") is calculated without considering the shares with suspended voting rights. It is published for proper public information in accordance with the AMF recommendation of July 17, 2007.

 

***

 

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the realtime in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.

 

 

Mauna Kea Technologies

investors@maunakeatech.com  

 

 

 

 

 

NewCap - Investor Relations

Aurélie Manavarere / Thomas Grojean

+33 (0)1 44 71 94 94

maunakea@newcap.eu 

 

1

See all MAUNA KEA TECHNOLOGIES news